Deutsche Bank AG acquired a new position in shares of QuidelOrtho Corporation (NASDAQ:QDEL - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 92,234 shares of the company's stock, valued at approximately $1,616,000. Deutsche Bank AG owned 0.14% of QuidelOrtho at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of the company. Hantz Financial Services Inc. lifted its position in shares of QuidelOrtho by 50.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company's stock worth $31,000 after purchasing an additional 362 shares during the last quarter. ProShare Advisors LLC increased its position in QuidelOrtho by 3.0% in the 4th quarter. ProShare Advisors LLC now owns 13,164 shares of the company's stock worth $376,000 after buying an additional 388 shares during the period. California State Teachers Retirement System lifted its holdings in shares of QuidelOrtho by 1.2% during the second quarter. California State Teachers Retirement System now owns 62,188 shares of the company's stock worth $1,792,000 after buying an additional 725 shares during the last quarter. Moody National Bank Trust Division boosted its position in shares of QuidelOrtho by 1.1% in the second quarter. Moody National Bank Trust Division now owns 70,748 shares of the company's stock valued at $1,239,000 after acquiring an additional 789 shares during the period. Finally, GAMMA Investing LLC increased its position in QuidelOrtho by 67.7% during the second quarter. GAMMA Investing LLC now owns 2,185 shares of the company's stock worth $38,000 after acquiring an additional 882 shares during the period. Institutional investors own 99.00% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the stock. Jefferies Financial Group reiterated a "hold" rating on shares of QuidelOrtho in a research note on Monday, June 29th. JPMorgan Chase & Co. lifted their target price on QuidelOrtho from $11.00 to $12.00 and gave the stock an "underweight" rating in a research report on Wednesday, July 1st. Citigroup lifted their price objective on QuidelOrtho from $13.00 to $18.00 and gave the stock a "neutral" rating in a report on Wednesday, July 8th. UBS Group reaffirmed a "neutral" rating and issued a $12.00 target price on shares of QuidelOrtho in a research report on Thursday, May 7th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of QuidelOrtho in a report on Friday, July 17th. Three analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Reduce" and an average target price of $13.62.
Get Our Latest Report on QDEL
QuidelOrtho Stock Down 3.8%
Shares of QDEL opened at $14.74 on Friday. The company has a market capitalization of $1.01 billion, a P/E ratio of -0.96 and a beta of 0.68. QuidelOrtho Corporation has a one year low of $9.92 and a one year high of $35.58. The business's 50 day simple moving average is $15.93 and its 200-day simple moving average is $16.04. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76.
QuidelOrtho (NASDAQ:QDEL - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.18. The firm had revenue of $630.90 million during the quarter, compared to the consensus estimate of $618.72 million. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%.The business's revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. As a group, sell-side analysts predict that QuidelOrtho Corporation will post 0.75 EPS for the current fiscal year.
QuidelOrtho Profile
(
Free Report)
QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.
The company's product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.
See Also
Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Corporation (NASDAQ:QDEL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider QuidelOrtho, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list.
While QuidelOrtho currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
